An example of the successful use of this strategy can be seen in a study by Gelderman et al. where the group designed a bispecific anti-CD55 and anti-Ep-CAM antibody that was able to precisely target and cause C3 deposition in cervical and colorectal carcinomas, which overexpress Ep-CAM (142, 143). The gene discussed is EPCAM; the disease is colorectal carcinoma.